ARKG Climbs +12% Over 30 Days and +29% This Quarter on Genomics AI Momentum
Key Takeaways
- ARKG gained roughly +12% over the last 30 days, extending a broader advance of about +29% over the past quarter.
- The move was led by AI-enabled diagnostics and multiomics holdings, most notably Tempus AI (TEM), on reimbursement and revenue catalysts.
- The fund is an actively managed, concentrated thematic ETF holding roughly 30 equities, with an expense ratio of 0.75% and effectively full healthcare exposure.
- Performance reflects the convergence of artificial intelligence and genomics rather than broad-market beta alone.
- ARKG carries elevated volatility, with annualized volatility above 40% and a high beta, amplifying both gains and drawdowns.
ARKG Overview and Portfolio Exposure
The ARK Genomic Revolution ETF is an actively managed, non-diversified thematic fund that seeks long-term growth of capital by investing at least 80% of its assets in companies relevant to the genomics revolution. That theme spans gene editing, targeted therapeutics, bioinformatics, molecular diagnostics, agricultural biotechnology, and enabling instrumentation and sequencing technologies.
The portfolio is concentrated, holding approximately 30 positions. Top weights include Twist Bioscience (TWST), Tempus AI (TEM), 10x Genomics (TXG), CRISPR Therapeutics (CRSP), CareDx (CDNA), Personalis (PSNL), Natera (NTRA), Illumina (ILMN), Absci (ABSI), and Eli Lilly (LLY). Exposure is essentially 100% healthcare, organized around technology buckets such as multiomic technologies, precision therapies, and programmable biology.
This structure explains the fund's outsized sensitivity to a narrow set of high-growth, mostly small- and mid-cap innovators. When the AI-and-genomics complex re-rates higher, a handful of heavily weighted names can move the entire fund quickly, in either direction. I also checked this using Tickeron’s AI Screener to see how the holdings compare across the sector.
ARKG Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARKG advanced approximately +12%, rising from the upper-$40s to above $53 on an adjusted closing basis. The climb was not linear; the fund consolidated through mid-September before accelerating sharply in the final stretch of the period.
The broader three-month trend was stronger still, with ARKG up roughly +29%. This reflects a multi-week uptrend punctuated by periodic pullbacks rather than a single one-day event, consistent with a thematic rotation into genomics and AI-driven healthcare rather than a short-lived headline spike.
What Drove ARKG Price in the Last 30 Days
The sharpest catalyst came from Tempus AI (TEM), a top holding that surged after management signaled clarity on Medicare reimbursement — projecting roughly $80 million to $100 million next year for its tissue-scanning test and $250 million to $300 million from its liquid-biopsy offering. The stock added about 15% in a single session amid a double-digit multi-day advance, lifting the broader diagnostics complex in which ARKG is heavily concentrated.
Strength also radiated across sequencing, liquid-biopsy, and molecular-diagnostics names such as CareDx and Twist Bioscience. More broadly, investors continued to reward the convergence of artificial intelligence with genomics — often described as "multiomics" — as sequencing-cost declines, CRISPR-based gene editing, and AI-assisted drug discovery translate into tangible clinical and commercial milestones. This re-rating drove outperformance among the small- and mid-cap innovators that dominate the fund's portfolio. From what I see, monitoring these catalysts with tools like Tickeron’s AI Trend Prediction Engine helps put the moves in context.
What Drove ARKG Performance Over the Last Quarter
Over the past three months, the advance was more structural than headline-driven. The multiomics theme staged a sustained re-rating as investors recognized that the combination of AI, falling sequencing costs, and CRISPR gene editing could meaningfully improve returns on research and development (R&D) across drug discovery and diagnostics.
Capital flows into thematic and innovation strategies supported the complex, while consolidation among top holdings added momentum. Tempus AI's agreement to acquire Personalis, one of the fund's other positions, underscored the industry's move toward integrated, data-driven precision-medicine platforms. Elevated Treasury yields and periodic geopolitical risk-off episodes created intermittent volatility, but the fund's underlying momentum remained intact through the period.
ARKG ETF Outlook: What Investors Should Watch Next
The fund's trajectory will remain closely tied to a few high-impact variables. Interest-rate expectations and inflation trends matter disproportionately for long-duration, high-beta growth equities, which are sensitive to shifts in discount rates. Any sustained rise in Treasury yields could pressure valuations even if underlying fundamentals hold.
Regulatory and reimbursement developments — particularly Medicare coverage decisions affecting liquid biopsy and molecular diagnostics — represent a key swing factor, given how directly they influence revenue visibility for top holdings such as Tempus AI. Clinical trial readouts across the gene-editing and targeted-therapy pipeline will also drive sentiment, as will the pace of M&A (mergers and acquisitions) and strategic partnerships in precision medicine.
Finally, investors should monitor capital flows into thematic ETFs and innovation strategies, which can amplify moves in both directions. ARKG's concentrated, non-diversified structure and elevated volatility mean the themes above are likely to remain the primary drivers of fund performance over the coming months. I'm watching this closely as the sector evolves.
Using Tickeron AI Tools for Research
In my view, investors seeking to monitor the genomics and AI-healthcare universe can benefit from Tickeron's AI Screener, an AI-powered stock and ETF discovery platform that scans thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool helps surface trending securities, breakout candidates, and new opportunities more efficiently. I use it regularly to build a more systematic view of the themes shaping this fast-moving sector and compare holdings like those in ARKG.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Momentum Indicator for ARKG turns positive, indicating new upward trend
ARKG saw its Momentum Indicator move above the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 80 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on September 17, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 242 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 194 of 215 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement